logo
Plus   Neg
Share
Email

General Mills Reaffirms FY19 Outlook - Quick Facts

General Mills Inc. (GIS) on Tuesday reaffirmed its financial outlook for the fiscal year ending May 26, 2019.

In conjunction with a presentation today at the Consumer Analyst Group of New York or CAGNY investor conference, General Mills maintained its forecast for fiscal 2019 organic net sales in a range between flat and up 1 percent. Including the impact of the Blue Buffalo acquisition, the company expects net sales to increase 9 to 10 percent in constant currency.

General Mills also affirmed its outlook for full-year constant-currency adjusted earnings per share to range between flat and down 3 percent. Constant-currency adjusted operating profit is expected to increase 6 to 9 percent.

The company also expects currency translation to reduce reported net sales by 1 to 2 percentage points in fiscal 2019, while it is not expected to have a material impact on full-year adjusted operating profit or adjusted earnings per share.

By combining consistent topline growth, margin expansion, and disciplined cash conversion and cash returns, General Mills expects to generate top-tier total shareholder returns over the long term.

For comments and feedback contact: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
MillerCoors LLC has filed a lawsuit against Anheuser-Busch Companies LLC, part of Anheuser-Busch InBev, alleging that Anheuser-Busch's ad campaigns associating MillerCoors' products, Miller Lite and Coor Light, with corn syrup is "false and misleading." During the Super Bowl, ABInBev ran an advertising campaign that mocked Miller Lite and Coors Light use corn syrup in brewing. Shares of Biogen Inc. are falling almost 28 percent in Thursday's trading after the company and Japanese drugmaker Eisai Co. said they will discontinue two late-stage trials for their experimental Alzheimer's drug, Aducanumab. The two Phase 3 trials, ENGAGE and EMERGE, are multi-center, randomized, double-blind, placebo-controlled, parallel-group studies designed to evaluate Aducanumab. The European Union on Wednesday ordered Alphabet Inc.'s Google to pay an antitrust fine of 1.49 billion euros for abusing its dominant position in the online search advertising intermediation market by preventing competition. This is the third antitrust fine by the EU against Google and it represents 1.29 percent of the tech giant's turnover in 2018.
Follow RTT